Abstract
It is now known that BNP and NT-proBNP levels are decreasing with increased BMI, regardless
of other metabolic syndrome (MS) constituents. Additionally, testosterone deficiency
may intensify frequency of ventricular rhythm disorders in obese individuals by inhibition
of the parasympathetic system. Determination of heart rhythm turbulence (HRT) is a
useful, noninvasive method used for evaluation of equilibrium of the vegetative system.
The aim of the study was to evaluate effect of testosterone therapy on HRT and NT-proBNP
levels in MS patients. Eighty males were qualified for the study. They were divided
into 3 groups: I (n=30), males with testosterone deficiency syndrome and metabolic
syndrome (MS+TDS+); II (n=25), males with MS+TDS–; III (n=25), healthy males. The
patients with MS+TDS+ received Omnadrem 250 in the form of intramuscular injections
for 9 weeks. Laboratory tests and 24-h Holter ECG were taken twice before the therapy
and directly after completion of the therapy. Males with MS+TDS+ more often presented
irregular HRT parameters and were characterised by lower NT-proBNP levels compared
to the healthy individuals. Testosterone replacement therapy caused improvement of
HRT and had no significant effect on the NT-proBNP level. Testosterone replacement
therapy and body weight reduction may significantly decrease negative consequences
of MS and TDS.
Key words
hypogonadism - testes - androgen - obesity
